Chemotherapy-induced thrombocytopenia: literature review [PDF]
Discover Oncology, 2023 Chemotherapy-induced thrombocytopenia (CIT) is a common condition that frequently results in reduced chemotherapy dosages, postponed treatment, bleeding, and unfavorable oncological outcomes.
Ai Gao, Linlin Zhang, Diansheng Zhong
doaj +4 more sources
Romiplostim in chemotherapy‐induced thrombocytopenia: A review of the literature [PDF]
Cancer MedicineChemotherapy‐induced thrombocytopenia (CIT) is a common challenge of cancer therapy and can lead to chemotherapy dose reduction, delay, and/or discontinuation, affecting relative dose intensity, and possibly adversely impacting cancer care.
Gerald A. Soff +4 more
doaj +4 more sources
Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia [PDF]
BMC Cancer, 2023 Background Thrombocytopenia is a common complication in cancer patients undergoing chemotherapy. Chemotherapy-induced thrombocytopenia (CIT) leads to dose reduction and treatment delays, lowering chemotherapy efficacy and survival rate.
Jiwon Shin +7 more
doaj +5 more sources
Chemotherapy‐induced thrombocytopenia: modern diagnosis and treatment [PDF]
British Journal of HaematologySummaryChemotherapy‐induced thrombocytopenia (CIT) is a common clinical problem in patients with solid tumour malignancies. Unlike nadir CIT which often resolves by the start of the following chemotherapy cycle, persistent CIT results in unacceptably low platelet counts at the beginning of a cycle lasting throughout multiple chemotherapy cycles ...
Hanny Al-Samkari, Andrew Song
exaly +4 more sources
Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors [PDF]
Research and Practice in Thrombosis and HaemostasisBased on real-world research, we aimed to systematically evaluate the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors.
Yuan Liu +6 more
doaj +4 more sources
Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use [PDF]
Research and Practice in Thrombosis and Haemostasis, 2022 Background Chemotherapy‐induced thrombocytopenia (CIT) is common during treatment with antineoplastic therapies and may adversely impact chemotherapy dose intensity. There is no approved therapy for CIT.
Cy R. Wilkins +7 more
doaj +4 more sources
Understanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment [PDF]
Current OncologyChemotherapy-induced thrombocytopenia (CIT) is a common yet underrecognized complication of systemic chemotherapy, particularly in gastrointestinal (GI) cancers. Despite progress in targeted and immune-based therapies, platinum-based and fluoropyrimidine
Supriya Peshin +5 more
doaj +5 more sources
Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice [PDF]
BMC Cancer, 2019 Background Chemotherapy-induced thrombocytopenia (CIT) is a potentially serious complication that can lead to chemotherapy dose delays, dose reductions, or discontinuation, and increases the risk of serious bleeding events.
Derek Weycker +6 more
doaj +5 more sources
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies [PDF]
Haematologica, 2022 Chemotherapy-induced thrombocytopenia (CIT) is a common complication of the treatment of non-hematologic malignancies. Many patient-related variables (e.g., age, tumor type, number of prior chemotherapy cycles, amount of bone marrow tumor involvement ...
David J. Kuter
doaj +4 more sources
Incidence, consequences, and predictors of serious chemotherapy‐induced thrombocytopenia in nasopharyngeal carcinoma [PDF]
Cancer Medicine, 2023 Objectives This study aimed to investigate the incidence, consequences, and predictors of serious chemotherapy‐induced thrombocytopenia (CIT) in nasopharyngeal carcinoma (NPC).
Lu‐Lu Zhang +11 more
doaj +4 more sources